Transcend Capital Advisors LLC Buys 23,474 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Transcend Capital Advisors LLC lifted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.2% in the 4th quarter, Holdings Channel reports. The fund owned 309,978 shares of the biopharmaceutical company’s stock after acquiring an additional 23,474 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Amicus Therapeutics were worth $4,399,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in FOLD. China Universal Asset Management Co. Ltd. increased its position in shares of Amicus Therapeutics by 97.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,368 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 3,638 shares in the last quarter. Park Avenue Securities LLC bought a new stake in shares of Amicus Therapeutics during the third quarter worth $128,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Amicus Therapeutics during the third quarter worth $134,000. Los Angeles Capital Management LLC bought a new stake in shares of Amicus Therapeutics during the third quarter worth $158,000. Finally, O Shaughnessy Asset Management LLC boosted its holdings in Amicus Therapeutics by 25.3% during the third quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 3,082 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently commented on FOLD. Cantor Fitzgerald restated an “overweight” rating and set a $22.00 target price on shares of Amicus Therapeutics in a report on Thursday, February 29th. JPMorgan Chase & Co. reduced their target price on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, March 18th.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 4,167 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total value of $58,338.00. Following the completion of the sale, the chief executive officer now owns 871,219 shares in the company, valued at $12,197,066. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider David Michael Clark sold 4,427 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total value of $61,978.00. Following the transaction, the insider now directly owns 253,664 shares of the company’s stock, valued at $3,551,296. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bradley L. Campbell sold 4,167 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the completion of the transaction, the chief executive officer now directly owns 871,219 shares in the company, valued at $12,197,066. The disclosure for this sale can be found here. Insiders sold a total of 48,108 shares of company stock worth $662,605 over the last quarter. 2.10% of the stock is currently owned by insiders.

Amicus Therapeutics Stock Up 1.1 %

FOLD traded up $0.11 during trading hours on Friday, hitting $10.28. 1,714,709 shares of the company’s stock were exchanged, compared to its average volume of 2,662,181. Amicus Therapeutics, Inc. has a 1-year low of $9.70 and a 1-year high of $14.57. The stock’s 50-day moving average is $11.95 and its two-hundred day moving average is $11.99. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of -20.16 and a beta of 0.75. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 2.42.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). The firm had revenue of $115.08 million during the quarter, compared to analyst estimates of $115.11 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. Sell-side analysts predict that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.